[go: up one dir, main page]

MX2018012498A - Benzodiazepinas inhaladas y nasales oralmente. - Google Patents

Benzodiazepinas inhaladas y nasales oralmente.

Info

Publication number
MX2018012498A
MX2018012498A MX2018012498A MX2018012498A MX2018012498A MX 2018012498 A MX2018012498 A MX 2018012498A MX 2018012498 A MX2018012498 A MX 2018012498A MX 2018012498 A MX2018012498 A MX 2018012498A MX 2018012498 A MX2018012498 A MX 2018012498A
Authority
MX
Mexico
Prior art keywords
nasal
benzodiazepines
orally inhaled
inhaled
orally
Prior art date
Application number
MX2018012498A
Other languages
English (en)
Inventor
Stöhr Thomas
Petersen Karl-Uwe
Jo Sakata Derek
Graham John
cooper Brett
Bevans Tatjana
Reilly Christopher
Original Assignee
Paion Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paion Uk Ltd filed Critical Paion Uk Ltd
Publication of MX2018012498A publication Critical patent/MX2018012498A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con un producto farmacológico inhalado y nasal oralmente (OINDP) que comprende una benzodiacepina, en particular Remimazolam.
MX2018012498A 2016-04-14 2017-04-18 Benzodiazepinas inhaladas y nasales oralmente. MX2018012498A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LU93027 2016-04-14
PCT/EP2017/059214 WO2017178663A1 (en) 2016-04-14 2017-04-18 Orally inhaled and nasal benzodiazepines

Publications (1)

Publication Number Publication Date
MX2018012498A true MX2018012498A (es) 2019-07-01

Family

ID=55949007

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012498A MX2018012498A (es) 2016-04-14 2017-04-18 Benzodiazepinas inhaladas y nasales oralmente.

Country Status (13)

Country Link
US (3) US20190175613A1 (es)
EP (2) EP4556068A3 (es)
JP (2) JP2019513796A (es)
KR (1) KR20180131617A (es)
CN (1) CN109641000A (es)
AU (1) AU2017248683A1 (es)
BR (1) BR112018071082A2 (es)
CA (1) CA3020722A1 (es)
EA (1) EA036520B1 (es)
ES (1) ES3027652T3 (es)
IL (1) IL262087B (es)
MX (1) MX2018012498A (es)
WO (1) WO2017178663A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111346058B (zh) * 2018-12-21 2022-05-17 宜昌人福药业有限责任公司 一种苯二氮䓬类化合物经鼻粘膜给药的药物组合物及其制备方法和用途
CN111346065B (zh) * 2018-12-21 2022-05-20 宜昌人福药业有限责任公司 苯二氮䓬类化合物口腔用固体药物组合物及其制备方法
CN111346098B (zh) * 2018-12-21 2022-05-27 宜昌人福药业有限责任公司 苯二氮䓬类化合物局部用药物组合物及制备方法和用途
EP3714884A1 (en) 2019-03-27 2020-09-30 Paion UK Limited Medical uses for benzodiazepines with a particular eeg pattern
CN112209932B (zh) * 2019-07-12 2023-03-24 成都倍特药业股份有限公司 一种化合物氢溴酸盐的新固体形态及其制备方法和用途
CN112462015B (zh) * 2020-11-18 2022-07-12 海南倍特药业有限公司 一种氢溴酸瑞马唑仑细菌内毒素的检测方法
CN112402428B (zh) * 2020-11-26 2022-02-25 李依泽 瑞马唑仑在制备治疗阿片类药物诱发的术后痛觉过敏的药物中的应用
CN114588164B (zh) * 2022-04-19 2023-08-11 天津医科大学总医院 瑞马唑仑在预防围术期低体温和寒战中的应用
AU2023394304A1 (en) * 2022-12-16 2025-05-22 Lts Lohmann Therapie-Systeme Ag Oromucosal delivery system containing remimazolam
WO2025038446A2 (en) * 2023-08-11 2025-02-20 Eagle Pharmaceuticals, Inc. Use of remimazolam for pediatric sedation
WO2025052259A1 (en) * 2023-09-05 2025-03-13 Reena Patel Ready to use compositions of remimazolam

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950664A (en) * 1988-09-16 1990-08-21 Rugby-Darby Group Companies, Inc. Nasal administration of benzodiazepine hypnotics
CA2143246C (en) 1994-03-16 2000-08-22 Thierry Godel Imidazodiazepines
FI972865L (fi) 1995-01-06 1997-09-03 Hoffmann La Roche Hydroksimetyyli-imidatsodiatseptiinejä ja niiden esterit
AU4382896A (en) 1995-02-02 1996-08-21 F. Hoffmann-La Roche Ag Acetylimidazobenzodiazepines
US7160880B1 (en) * 1999-05-14 2007-01-09 Cenes Limited Short-acting benzodiazepines
GB9911152D0 (en) 1999-05-14 1999-07-14 Glaxo Group Ltd Short-acting benzodiazepines
SI2081921T1 (sl) * 2006-07-10 2011-01-31 Paion Uk Ltd Soli benzodiazepina s kratkotrajnim učinkom ter njihove polimorfne oblike
GB0613692D0 (en) * 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts
GB0613693D0 (en) 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts (3)
GB0716907D0 (en) * 2007-08-31 2007-10-10 Archimedes Dev Ltd Pharmaceutical powder compositions
EP2305647A1 (en) 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
EP2450039A1 (en) * 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
US20130309306A1 (en) 2010-12-01 2013-11-21 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
EP2694076A4 (en) * 2011-04-01 2014-08-27 Cpex Pharmaceuticals Inc NASAL FORMULATIONS FROM BENZODIAZEPINE
CN102964349A (zh) 2011-08-31 2013-03-13 江苏恒瑞医药股份有限公司 苯并二氮杂*衍生物的托西酸盐及其多晶型、它们的制备方法和用途
PE20150683A1 (es) * 2012-05-22 2015-06-03 Paion Uk Ltd Composiciones que comprenden benzodiazepinas de accion corta
SG11201501358SA (en) * 2012-08-31 2015-04-29 Paion Uk Ltd Method for administering hypnotic/sedative agent
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
CN103232454A (zh) * 2013-05-05 2013-08-07 王元青 治疗精神疾病的药物
CN107198691A (zh) * 2016-03-17 2017-09-26 江苏恒瑞医药股份有限公司 一种瑞马唑仑的药物组合物

Also Published As

Publication number Publication date
JP2021185170A (ja) 2021-12-09
EP4556068A3 (en) 2025-07-23
CA3020722A1 (en) 2017-10-19
EA201892327A1 (ru) 2019-04-30
AU2017248683A1 (en) 2018-10-25
EA036520B1 (ru) 2020-11-19
EP3442539A1 (en) 2019-02-20
CN109641000A (zh) 2019-04-16
IL262087A (en) 2018-11-29
EP4556068A2 (en) 2025-05-21
EP3442539C0 (en) 2025-04-09
US20190175613A1 (en) 2019-06-13
IL262087B (en) 2021-09-30
JP2019513796A (ja) 2019-05-30
KR20180131617A (ko) 2018-12-10
BR112018071082A2 (pt) 2019-02-05
ES3027652T3 (en) 2025-06-16
US20220273672A1 (en) 2022-09-01
EP3442539B1 (en) 2025-04-09
US20200253983A1 (en) 2020-08-13
WO2017178663A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
MX2018012498A (es) Benzodiazepinas inhaladas y nasales oralmente.
PH12019501970A1 (en) Pharmaceutical compositions for combination therapy
MX393936B (es) Combinacion de elafibranor o derivados del mismo con un agente anti-ehna, antifibrotico o anticolestasico
PL3694349T3 (pl) Inhalator, w szczególności elektroniczny produkt papierosowy
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
PL3694350T3 (pl) Inhalator, zwłaszcza elektroniczny produkt papierosowy
PH12019501301A1 (en) Pharmaceutical compositions for combination therapy
MX2017004473A (es) Formulaciones de betalactamasa y usos de las mismas.
MX2017016802A (es) Formulaciones farmaceuticas.
IL272637A (en) History of benzaimidazole, their preparation and medicines containing them
AU201612882S (en) Oral care implement
PH12016501841A1 (en) Immunosuppressant formulation
ZA201902008B (en) Composition, in particular a preventive and curative pharmaceutical composition, made from peroxometallate
MX2018005358A (es) Comprimido de dosis alta que contiene mesalazina optimizado.
MX2019015167A (es) Farmacos antivirales.
PH12013000251A1 (en) Electrostatic discharge devices and method of making the same
MX2020005472A (es) Sistemas de administración de fármacos a base de maitansinoide.
MX2016002560A (es) Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
WO2014154844A8 (de) Stabilisiertes polyribonucleotid codierend für ein elastisches faserprotein
IN2013MU03370A (es)
PH12017501979A1 (en) Pharmaceutical compound
HUE057090T2 (hu) BI-heteroaril-szubsztituált 1,4-benzodiazepinek és alkalmazásuk rák kezelésében
PH12017500071A1 (en) Therapeutic agent for keratoconjunctive disorder
HK1247917A1 (zh) 与金属和/或自由基螯合构型有关的邻伯二胺，及其抗羰基和氧化应激的活性，及其用途
CA3067911C (en) COMPOSITIONS INTENDED FOR THE PREVENTION AND TREATMENT OF ACUTE KIDNEY INJURY